NewAmsterdam Pharma Company N.V. Board of Directors

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Dr. Michael Harvey Davidson FACC, Facp., M.D.

Dr. Michael Harvey Davidson FACC, Facp., M.D.

CEO, President, Executive Board Member & Director

Dr. Sheng Cui Ph.D.

Dr. Sheng Cui Ph.D.

Chief Manufacturing Officer

Mr. Mayur Amrat Somaiya

Mr. Mayur Amrat Somaiya

Chief Financial Officer

Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.

Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.

Founder, Chief Scientific Officer, Member of Executive Board & Director

Dr. Marc Ditmarsch M.D.

Dr. Marc Ditmarsch M.D.

Chief Development Officer

Mr. Bob Rambo

Mr. Bob Rambo

Executive Vice President of Marketing

Mr. Matthew Philippe

Mr. Matthew Philippe

Executive VP &Head of Investor Relations

Mr. Douglas F. Kling

Mr. Douglas F. Kling

Chief Operating Officer

Ms. Louise Kooij

Ms. Louise Kooij

Chief Accounting Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.